We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Exelgen Announces Partnerships with Two European Biotechnology Companies
News

Exelgen Announces Partnerships with Two European Biotechnology Companies

Exelgen Announces Partnerships with Two European Biotechnology Companies
News

Exelgen Announces Partnerships with Two European Biotechnology Companies

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Exelgen Announces Partnerships with Two European Biotechnology Companies"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Exelgen Ltd. (formerly Tripos Discovery Research) has announced significant new collaborations with two prominent European-based Biotechnology companies. Because of the proprietary nature of the collaborations both companies have declined to be identified or disclose the contract values at this time. One company is a long standing client, the other a new client.

The partnerships encompass a range of collaborative research activities including medicinal chemistry and application of Exelgen’s LeadHopping® technology to identify and progress lead compound series into preclinical studies.

“The decision by these premiere biotechnology companies to select Exelgen as their drug discovery partner underscores the quality of our work, the innovation we bring to our partners and our solid reputation for success in this field," said Mark Warne, Managing Director of Exelgen.

"As we enter 2008, we are committed to expanding our capabilities to provide clients an integrated drug discovery platform from hit identification up through IND enabling studies. We are currently engaged in more high value discovery research programs than ever before, and we look forward to generating excellent results for our clients."

Advertisement